AI assistant
MACROGENICS INC — Director's Dealing 2021
Mar 10, 2021
34129_dirs_2021-03-09_4762082f-6e58-41aa-8d67-da2ea92a15ef.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MACROGENICS INC (MGNX)
CIK: 0001125345
Period of Report: 2021-03-08
Reporting Person: Peters Jeffrey Stuart (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-08 | Common Stock | M | 21749 | $11.50 | Acquired | 21749 | Direct |
| 2021-03-08 | Common Stock | S | 21749 | $26.50 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-08 | Employee stock option (right to buy) | $11.5 | M | 21749 | Disposed | 2030-02-20 | Common Stock (21749.0) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2019.
F2: This transaction was executed in multiple trades at prices ranging from $26.50 to $26.63. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter.